Follow Adesis On Twitter!

Meet Adesis at Informex, Booth 1165

Adesis, Inc. is a contract research organization (CRO) supporting the pharmaceutical and biopharmaceutical industry, biomaterials and catalysts industry. The life science industry has embraced the philosophy of outsourcing reference standards (competitor's drugs), targets, scaffolds, building blocks and advanced intermediates. Outsourcing allows medicinal chemists to focus on design and assembly of new targets for pharmacological evaluation and streamlines the early stage drug discovery process. Similarly, other chemistry-based research organizations (catalysts, biomaterials and fragrances) have accepted similar modus of operendi in order to maximize cost controls, while having timely project successes.

The core foundation of Adesis, Inc. is attributed to our experienced chemists with the expertise to conduct complex multi-step synthetic sequences (typical range of 2 - 20 steps).

Adesis News


News

March 2013

Adesis joins DE Sustainable Chemistry Alliance (DESCA).

May 2012

The Adesis May Newsletter has been released. Current issue. Click here

April 2012

Adesis has become a member of SOCMA, the Society of Chemical Manufacturers and Affiliates, Inc., which is the only US based trade association dedicated solely to the batch, custom, and specialty chemical industry. SOCMA supports the industry with initiatives that promote commercial and networking opportunities, public relations and education, and passage of rational laws and regulations. Adesis is one of the few smaller specialty and services members with less than 75 employees.

February 2012

Read the feature article about Novel Imidazo[1,2-a] Pyridines in the Adesis February Newsletter. Current issue. Click here

January 2012

The Adesis January Newsletter has been released. To read the current issue. Click here

November 2011

The Adesis November Newsletter has been released. To read the current issue. Click here

October 2011

The Adesis October Newsletter has been released. To read the current issue. Click here

September 12, 2011

Adesis, Inc. and Aldrich Chemical Company have agreed to a collaboration that enables Adesis to feature select products from its Adesis Catalog of Heterocyclic Intermediate in the Sigma-Aldrich online catalog. Approximately 1,300 products from the current Adesis Catalog of Heterocyclic Intermediates will be available at sigma-aldrich.com. These include in-stock and scalable novel* heterocyclic building blocks and intermediates that are highly valued for their drug-like qualities, catalyst ligand potential, and materials science properties. Notably, Adesis will continue to i) introduce new molecular entities weekly, and ii) assure that all building blocks are immediately available.

The inclusion of these heterocyclic compounds in the highly regarded Sigma-Aldrich online catalog now provides for their greater accessibility through the well established, global Sigma-Aldrich distribution network. Aldrich Chemistry and Adesis share many core traits in their approach to serving customers, including high purity, reliable stock, and rapid response to inquiries. These qualities have made Aldrich Chemistry a recognized global leader in the chemical industry, and Adesis is excited to be included.

* novel is defined as: At the time of their introduction over 80% of the Adesis catalog compounds are unregistered and do not have CAS numbers.

September, 2011

The Adesis September Newsletter has been released. To read the current issue. Click here

August 2011

The Adesis August Newsletter has been released. To read the current issue. Click here

July 2011

Adesis is proud to welcome Dr. Amos B. Smith, III and Dr. Martin Semmelhack to the Scientific Advisory Board. To read more about the Board members Click here

June2011


Adesis has a Whitepaper, “Orthogonally-functionalized Pyridines from a Drug Discovery and Optimization Perspective”, featured on 20/20 Pharma's website. To read or download the paper Click here

May 2011


Ving Lee and Ronald Yarger participated in 20/20 Pharma's Podcast "Working Hand-in-Hand for the Future of Pharma Outsourcing". Visit 20/20 Pharma's website to listen to the podcast Click here

March 2011

Adesis attended the Spring ACS meeting - Booth 951

January 2011

Adesis is proud to announce that Chemie Brunschwig is a new distribution partner located in Switzerland, effective January 1, 2011.

October 2010

Ving J. Lee, CEO/CSO of Adesis was quoted in the Chemical & Engineering News, October 4, 2010 issue. The article was “Improving Forecast” and the following excerpts include a few of his quotes:

"For example, business is good at Adesis, according to Chief Executive Officer Ving J. Lee."

Lee acknowledged the tough funding climate for biotech companies, but he argued that it can force them to more prudently use what money they do raise. "You don't want to spend expensive venture capital money to build infrastructure he observed. You should use it to buy services instead."

"Although U.S. CROs have a reputation for mainly serving small biotech firms that aren't able to manage an offshore project, Adesis has larger clients as well, Lee said."

To read the entire article, access this link to Chemical & Engineering News October 4th issue: Click here

June 2010

Dr. Andrew Cottone received the ACS's Younger Chemists Committee's 2010 Leadership Development Award. To read the entire article, access the link on the ACS website: Click here

March 2010

Adesis has recently expanded the management team to include Dr. Ronald Yarger, Director of Business Development. His contact information is:

Office: 302-261-3383
Cell: 302-358-8837
Email: 


February 2010

Ving J. Lee, CEO/CSO of Adesis was quoted in the Chemical & Engineering News, February 8, 2010 issue. The article was “Skills for Success” and the following excerpts include a few of his quotes:

However. Not all scientists are cut out for teamwork, says Ving J. Lee, who serves both as chief executive officer and chief scientific officer of contract research organization (CRO) Adesis, in New Castle, Del., and as senior vice president of research at Limerick BioPharma, in South San Francisco. When interviewing or considering job candidates, Lee looks for clues that might indicate that a scientist “lacks a proclivity for collaboration,” he says. “If every line in a resume or introduction letter begins with the word ‘I,’ it may be an indication that the candidate is focused on his or her own ego and does not understand that research is a team endeavor.”

“Fifteen years ago, a Ph.D.-level synthetic organic chemist hired into a large pharmaceutical company would undoubtedly be doing his own lab work at the bench, but now more and more of these scientists are involved in managing the work that is being sent to CROs,” Lee says. Those scientists must now have the skills “to communicate and cooperate with CROs or other labs to facilitate the research in an effective and professional manner,” he says.

Although scientists can sharpen their professional skills in special classes and courses, sometimes they can reach the same goal through less formal means. Often, “these skills are best learned by peer interaction and mentoring and through real life experiences,” says Adesis’ Lee.

To read the entire article, access this link to Chemical & Engineering News February 8th issue: Click here
  • 3,4-Dihydro-2H-pyrano[2,3-b]pyridine-6-carbaldehyde
  • 6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-pyrano[2,3-b]pyridine
  • 1-tert-Butyl 5-methyl 1H-pyrazolo[3,4-b]pyridine-1,5-dicarboxylate
  • 3,4-Dihydro-2H-pyrano[2,3-b]pyridin-6-amine
  • 5-Chloro-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid
  • 5-Chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid
  • 5-Chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine
  • 5-Fluoro-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid
  • 7-Chloro-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-6-carbaldehyde
  • Methyl 1H-pyrrolo[2,3-b]pyridine-6-carboxylate
  • Methyl 7-chloro-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-8-carboxylate
  • tert-Butyl 1H-pyrrolo[2,3-b]pyridin-6-ylcarbamate